Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Sanofi SA — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $13.05, while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while YieldMax NVDA Option Income Strategy ETF pays none. Which is the better fit depends on your goals.
| NVDY | SNY | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $17.96 | $52.34 |
52-Week Low | $11.58 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY trades at $13.055, up 2.55% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividend income, with recent payouts ranging from $0.09 to $0.15 per share. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights the fund's strategy of selling NVIDIA call options to fund distributions, attracting income-focused investors.
The outlook for NVDY hinges on NVIDIA's volatility, which drives option premiums and dividends. However, investors sacrifice significant upside potential in NVIDIA's stock gains. Risks include underperformance versus direct NVIDIA ownership and fee drag. The ETF suits income seekers but may disappoint those seeking capital appreciation.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
